-
Something wrong with this record ?
Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine
A. Brisuda, J. Háček, M. Čechová, P. Škapa, M. Babjuk,
Language English Country Great Britain
Document type Journal Article
PubMed
30943322
DOI
10.1111/cyt.12698
Knihovny.cz E-resources
- MeSH
- Ki-67 Antigen immunology MeSH
- Cytodiagnosis * MeSH
- Immunohistochemistry MeSH
- Humans MeSH
- Minichromosome Maintenance Complex Component 2 immunology MeSH
- Urine cytology MeSH
- Biomarkers, Tumor metabolism MeSH
- Tumor Suppressor Protein p53 immunology MeSH
- Urinary Bladder Neoplasms diagnosis pathology MeSH
- Cell Cycle Proteins immunology MeSH
- Antibodies, Neoplasm immunology MeSH
- ROC Curve MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Neoplasm Grading MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: Immunocytochemistry has attained a marginal role in urology so far. Combining the morphological and immunophenotypical changes of the urothelial cells retrieved from urine is a logical approach. The study aimed to analyse the diagnostic potential of immunocytological staining in the detection of high-grade and low-grade urothelial carcinoma. METHODS: Freshly voided urine was collected from 152 consecutive individuals, cytology classes were determined and cell blocks produced. A total of 77 patients were diagnosed with urothelial carcinoma and 75 patients had various benign urological conditions. Immunocytochemistry was performed using four antibodies: p53, MCM2, MCM5 and Ki-67. A diagnostic power to detect low grade and high-grade urothelial carcinoma was analysed for each antibody and their combinations with cytology. RESULTS: There were no significant differences between patients with low-grade tumours and control group. Antibodies p53 and Ki-67 slightly improved the sensitivity of urinary cytology while maintaining its specificity. The best negative predictive value was demonstrated in combinations of cytology and MCM5 (88.9%) and cytology, p53 and MCM5 (90.6%). In the diagnosis of high-grade tumours, all antibodies apart from MCM2 yielded better sensitivity and specificity than cytology alone (receiver operating characteristic curves: p53 = 0.853, MCM5 = 0.931, and Ki-67 = 0.895). Combined with cytology, the sensitivities went even higher for the cost of lower specificity. The best diagnostic performance was observed in the combination of MCM5 and Ki-67 (sensitivity = 96.2%; specificity = 80%). CONCLUSIONS: Immunocytochemistry with p53, MCM5 and Ki-67 antibodies can improve the diagnostic power of urinary cytology in the detection and follow-up of urinary bladder urothelial carcinoma.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025683
- 003
- CZ-PrNML
- 005
- 20201222154031.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cyt.12698 $2 doi
- 035 __
- $a (PubMed)30943322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Brisuda, Antonín $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine / $c A. Brisuda, J. Háček, M. Čechová, P. Škapa, M. Babjuk,
- 520 9_
- $a OBJECTIVE: Immunocytochemistry has attained a marginal role in urology so far. Combining the morphological and immunophenotypical changes of the urothelial cells retrieved from urine is a logical approach. The study aimed to analyse the diagnostic potential of immunocytological staining in the detection of high-grade and low-grade urothelial carcinoma. METHODS: Freshly voided urine was collected from 152 consecutive individuals, cytology classes were determined and cell blocks produced. A total of 77 patients were diagnosed with urothelial carcinoma and 75 patients had various benign urological conditions. Immunocytochemistry was performed using four antibodies: p53, MCM2, MCM5 and Ki-67. A diagnostic power to detect low grade and high-grade urothelial carcinoma was analysed for each antibody and their combinations with cytology. RESULTS: There were no significant differences between patients with low-grade tumours and control group. Antibodies p53 and Ki-67 slightly improved the sensitivity of urinary cytology while maintaining its specificity. The best negative predictive value was demonstrated in combinations of cytology and MCM5 (88.9%) and cytology, p53 and MCM5 (90.6%). In the diagnosis of high-grade tumours, all antibodies apart from MCM2 yielded better sensitivity and specificity than cytology alone (receiver operating characteristic curves: p53 = 0.853, MCM5 = 0.931, and Ki-67 = 0.895). Combined with cytology, the sensitivities went even higher for the cost of lower specificity. The best diagnostic performance was observed in the combination of MCM5 and Ki-67 (sensitivity = 96.2%; specificity = 80%). CONCLUSIONS: Immunocytochemistry with p53, MCM5 and Ki-67 antibodies can improve the diagnostic power of urinary cytology in the detection and follow-up of urinary bladder urothelial carcinoma.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protilátky nádorové $x imunologie $7 D000912
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a proteiny buněčného cyklu $x imunologie $7 D018797
- 650 12
- $a cytodiagnostika $7 D003581
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a antigen Ki-67 $x imunologie $7 D019394
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a MCM komplex, komponenta 2 $x imunologie $7 D064111
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a nádorový supresorový protein p53 $x imunologie $7 D016159
- 650 _2
- $a nádory močového měchýře $x diagnóza $x patologie $7 D001749
- 650 _2
- $a moč $x cytologie $7 D014556
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Háček, Jaromír $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Čechová, Marcela $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Škapa, Petr $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Babjuk, Marek $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00009532 $t Cytopathology : official journal of the British Society for Clinical Cytology $x 1365-2303 $g Roč. 30, č. 5 (2019), s. 510-518
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30943322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222154026 $b ABA008
- 999 __
- $a ok $b bmc $g 1599828 $s 1116369
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 30 $c 5 $d 510-518 $e 20190520 $i 1365-2303 $m Cytopathology $n Cytopathology $x MED00009532
- LZP __
- $a Pubmed-20201125
